Multiple Myeloma Market Size and Share Analysis, Recent Developmental Activities, Key Growth Factors, Leading Companies, Emerging Therapies, and Epidemiology Forecast 1
Delveinsight Business Research LLP
DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Multiple Myeloma Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Chine and Japan.

The Multiple Myeloma Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Multiple Myeloma market Size from 2017 to 2030 segmented by eight major markets.

The report provides a detailed current Multiple Myeloma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Multiple Myeloma Market

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system.

Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. Multiple Myeloma is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.

Multiple Myeloma Market Key Facts

  • In 2020, the total incident case of Multiple Myeloma was 91,693 in the 8MM.

  • The United States, in 2020, accounted for 32,270 cases which is expected to increase during the forecast period.

  • In the 8MM, the total gender-specific cases of Multiple Myeloma were 43,910 cases for males and 36,805 cases for females in the year 2020.

  • According to DelveInsight’s analysis, in the 8MM, China reported 21,116 cases which accounted for nearly 23% of the total 8MM cases, in the year 2020.

  • Among the EU-5 countries, the highest number of cases of Multiple myeloma was in Germany, with 7,600 cases in the year 2020.

  • According to DelveInsight’s analysis males are affected more, in the case of Multiple Myeloma (MM) as compared to females in the 8MM.

Key Benefits of Multiple Myeloma Market Report

  • The market report provides an in-depth analysis of Multiple Myeloma Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the eight major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK), China and Japan.

  • The report will help in developing business strategies by understanding the Multiple Myeloma Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Multiple Myeloma current treatment practices, emerging drugs, market share of the individual therapies in the eight major markets.

  • The report provides a detailed assessment of the Multiple Myeloma market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Multiple Myeloma Market 

The Multiple Myeloma market size is expected to increase during the forecast period owing to the increasing incidence of Multiple Myeloma, label expansion of current therapies, and rising awareness of marketed therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Multiple Myeloma market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Multiple Myeloma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request for Sample @ Multiple Myeloma Therapeutics Market Assessment

Multiple Myeloma Epidemiology

The epidemiology section covers insights about the historical and current Multiple Myeloma patient pool and forecasted trends for every eight major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched in the market during the study period. The analysis covers Multiple Myeloma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Multiple Myeloma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

The dynamics of the Multiple Myeloma market is anticipated to change in the coming years owing to the rise in novel drugs and the rise in healthcare spending across the world. 

Key companies in the Multiple Myeloma therapeutics domain includes:

  • Pfizer

  • Takeda

  • Amgen

  • Abbvie

  • AbbVie

  • Roche

  • AstraZeneca

  • GlaxoSmithKline

  • Bristol-Myers Squibb

  • Janssen Research & Development

  • Merck Sharp & Dohme Corp.

And many others.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/multiple-myeloma-market

Multiple Myeloma Therapies covered in the report include:

  • Descartes-11

  • Venetoclax

  • REGN5458

  • Iberdomide

  • Imfinzi (Durvalumab;MEDI4736)

  • Braftovi (encorafenib)

  • Motixafortide (BL-8040)

  • Felzartamab (MOR202)

  • Chidamide (Epidaza)

  • Keytruda (Pembrolizumab)

  • Cetrelimab (JNJ-63723283)

  • Ciltacabtagene Autoleucel (cilta-cel/JNJ-68284528/LCAR-B38M)

And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Multiple Myeloma Competitive Intelligence Analysis

4. Multiple Myeloma Market Overview at a Glance

5. Multiple Myeloma Disease Background and Overview

6. Multiple Myeloma Patient Journey

7. Multiple Myeloma Epidemiology and Patient Population

8. Multiple Myeloma Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Myeloma Unmet Needs

10. Key Endpoints of Multiple Myeloma Treatment

11. Multiple Myeloma Marketed Products

12. Multiple Myeloma Emerging Therapies

13. Multiple Myeloma eight Major Market Analysis

14. Attribute Analysis

15. Multiple Myeloma Market Outlook (7 major markets)

16. Multiple Myeloma Access and Reimbursement Overview

17. KOL Views on the Multiple Myeloma Market.

18. Multiple Myeloma Market Drivers

19. Multiple Myeloma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/multiple-myeloma-market

Latest Reports By DelveInsight

Multiple Myeloma (MM) Pipeline Insights

Multiple Myeloma Pipeline Insights 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario & growth prospects across the Multiple Myeloma market.

Corneal Endothelial Dystrophy Market

DelveInsight’s “Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/